StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Stock analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Monday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Down 0.0 %

Shares of TherapeuticsMD stock opened at $1.79 on Monday. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $3.70. The firm’s 50-day moving average price is $1.77 and its two-hundred day moving average price is $1.97.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

A number of large investors have recently modified their holdings of TXMD. ADAR1 Capital Management LLC acquired a new position in TherapeuticsMD in the fourth quarter valued at approximately $612,000. Clearline Capital LP lifted its holdings in TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after buying an additional 101,282 shares during the period. Finally, Prosperity Consulting Group LLC acquired a new position in TherapeuticsMD in the first quarter valued at approximately $56,000. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.